The Italian Competition Authority launches an investigation against pharmaceutical companies suspected of restricting drug sales (Roche, Novartis)

On February 6, 2013, the Italian Competition Authority ("ICA") launched a cartel investigation against Hoffmann-La Roche ("Roche"), Novartis, their respective Italian subsidiaries, and Genentec, a US company controlled by Roche and in which Novartis holds a 33% shareholding. The companies are suspected to have agreed to restrict the therapeutic applications of Avastin, a drug marketed by Roche, in order to advantage the sales of Lucentis, which is marketed by Novartis. Avastin is a drug patented by Genentech. It is treatment for patients with colon cancer, but it also cures certain ophtalmic diseases (i.e. wet age-related macular degeneration). However, the use of Avastin for the cure of ophthalmic diseases is possible only “off-label”, because Roche has not requested the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Studio Legale Scoccini E Associati (Rome)

Quotation

Giovanni Scoccini, The Italian Competition Authority launches an investigation against pharmaceutical companies suspected of restricting drug sales (Roche, Novartis), 6 February 2013, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 51809

Visites 313

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues